阿托伐他汀短期治疗对冠心病和扩张型心肌病患者血管性血友病因子的影响

Effect of short-term atorvastatin on von Willebrand factor in patients with coronary disease or dilated cardiomyopathy

目的探讨短期(4周)应用阿托伐他汀治疗后,冠心病和扩张型心肌病(DCM)患者血清血管性血友病因子(vWF)的变化情况。方法将60例冠心病患者和30例DCM患者分别随机分为治疗组和对照组,冠心病每组各30例,DCM每组各15例,各组均给于相同常规治疗方案,治疗组加用阿托伐他汀治疗4周。治疗前后分别检测血清中vWF的水平。结果治疗开始前,冠心病和DCM治疗组与对照组vWF水平相比,差异均无统计学意义(P均>0.05),经4周治疗后,各组vWF水平均有明显下降(P均<0.05),其中冠心病和DCM治疗组与对照组相比降低更明显(P均<0.05)。结论经阿托伐他汀治疗4周后,可降低冠心病和DCM患者血清vWF的水平,提示阿托伐他汀可减轻冠心病和DCM患者的血管内皮损伤。

Objective To evaluate the effect of short-term atorvastatin on the plasma yon Willebrand factor （vWF） in patients with coronary disease （CD） or dilated cardiomyopathy （DCM）. Methods Sixty patients with CD and 30 patients with DCM were enrolled and randomly divided into 4 groups respectively： CD treatment group （30 cases）, CD control group （30 cases）, DCM treatment group （15 cases） and DCM control group （15 cases）. All the patients received the same therapy, while patients in the treatment groups were given atorvastatin for another 4 weeks. The vWF levels were detected before and after the treatment. Results No significant differences were found in the vWF levels in all the groups before the treatment started. After 4 weeks treatment, the vWF levels decreased significantly in all the groups （all P〈0.05）, and in the treatment groups the levels reduced more obviously as compared with the controls （all P〈 0.05）. Conclusion Atorvastatin treatment for four weeks could decrease the vWF levels in patients with CD or DCM, which implied that atorvastatin could attenuate the vascular endothelial cells damage in those patients.